US Generics Market: Industry Trends, Competitive Landscape, Opportunities and Outlook
The report entitled “US Generics Market: Industry Trends, Competitive Landscape, Opportunities and Outlook” provides a comprehensive insight into the historical and current trends as well as the future prospects of the US generics market. This study serves as an exceptional tool to understand the sales trends, volume trends, growth, key segments, competitive structure, regulations, major manufacturer, major distributors, top drugs, manufacturing requirements, opportunities and future prospects of the US generics market. This report can serve as an excellent guide for manufacturers, consultants, researchers, marketing strategists and all those who plan to foray into the US generics market in any form.
What We Have Achieved in This report?
What We Have Achieved in This report?
- Historical, current and future sales trends in the US generics market
- Historical, current and future prescription trends in the US generics market
- Performance of the US generics market compared to the pharmaceutical market
- Performance of the US generics market compared to other major markets
- Market structure of the US generics market
- Competitive landscape in the US generics market
- Top US generic drug manufacturers and their market shares
- Distribution of generics in the US
- Top US generic distributors and their market shares
- Most prescribed generic drugs in the US
- Pricing analysis of generic drugs
- Value chain analysis of generic drugs in the US
- Regulations in the US generics market
- Manufacturing process of generics
- Machinery and raw material requirements for manufacturing generics
- Key success and risk factors in the US generics market
1 RESEARCH METHODOLOGY AND MARKET DEFINITIONS
2 REPORT SUMMARY
3 US GENERICS MARKET – INTRODUCTION
3.1 What are Generics?
3.2 Unbranded and Branded Generics
3.3 Authorized Generics
3.4 Commoditised and Specialty Generics
4 WHY IS THE US GENERICS MARKET SO LUCRATIVE
4.1 Patent Expiry of Blockbuster Drugs
4.2 Significant Price Differential Between Generics and Innovator Drugs
4.3 Savings for the Government and Third Party Payers
4.4 Incentives for Dispensing and Prescribing Generics
4.5 Reimbursement and Lower Copayments
4.6 Biosimilars
5 GLOBAL GENERICS MARKET
5.1 Current and Historical Market Trends
5.2 Market Breakup by Country: The United States Represents the World’s Biggest Market
5.3 Market Forecast
6 US GENERICS MARKET
6.1 US Pharmaceutical Market – Current and Historical Market Trends
6.2 US Pharmaceutical Market – Share of Branded and Generic Drugs
6.3 US Generics Market – Current and Historical Sales Trends
6.4 US Generics Market – Current and Historical Volume Trends
6.5 US Generics Market – Market Breakup By Segment
7 US GENERICS MARKET- COMPETITIVE LANDSCAPE
7.1 US Generics Market – Competitive Structure
7.2 US Generics Market – Sales Breakup of Key Players
7.3 US Generics Market – Volume Breakup of Key Players
7.4 US Generics Market – Most Prescribed Generic Drugs
7.5 US Generics Market – Market Breakup By Distribution
7.6 US Generics Market – Pricing Dynamics
8 US GENERICS MARKET – VALUE CHAIN ANALYSIS
8.1 Research and Development
8.2 Manufacturing
8.3 Marketing and Distribution
9 REGULATIONS IN THE US GENERICS INDUSTRY
9.1 Overview of Pharmaceutical Regulations
9.2 Drug Applications
9.3 Patents and Market Exclusivity
9.4 Regulatory Requirement For Generics
9.5 The Hatch-Waxman Act
9.6 Possible Certifications
9.7 Other Important Considerations
10 US GENERICS MARKET: KEY SUCCESS FACTORS
11 US GENERICS MARKET: ROAD BLOCKS
12 REQUIREMENTS FOR SETTING UP A GENERIC DRUG MANUFACTURING PLANT
12.1 Manufacturing Process
12.2 Raw Material Requirements
12.3 Machinery and Infrastructure Requirements
13 US GENERIC MARKET – KEY COMPANY PROFILES
13.1 Teva
13.2 Mylan
13.3 Actavis
13.4 Sandoz
13.5 Sun Pharma
13.6 Par Pharmaceuticals
13.7 Endo Pharmaceuticals
13.8 Lupin Pharmaceuticals
13.9 Dr Reddy’s
13.10 Hospira
2 REPORT SUMMARY
3 US GENERICS MARKET – INTRODUCTION
3.1 What are Generics?
3.2 Unbranded and Branded Generics
3.3 Authorized Generics
3.4 Commoditised and Specialty Generics
4 WHY IS THE US GENERICS MARKET SO LUCRATIVE
4.1 Patent Expiry of Blockbuster Drugs
4.2 Significant Price Differential Between Generics and Innovator Drugs
4.3 Savings for the Government and Third Party Payers
4.4 Incentives for Dispensing and Prescribing Generics
4.5 Reimbursement and Lower Copayments
4.6 Biosimilars
5 GLOBAL GENERICS MARKET
5.1 Current and Historical Market Trends
5.2 Market Breakup by Country: The United States Represents the World’s Biggest Market
5.3 Market Forecast
6 US GENERICS MARKET
6.1 US Pharmaceutical Market – Current and Historical Market Trends
6.2 US Pharmaceutical Market – Share of Branded and Generic Drugs
6.3 US Generics Market – Current and Historical Sales Trends
6.4 US Generics Market – Current and Historical Volume Trends
6.5 US Generics Market – Market Breakup By Segment
7 US GENERICS MARKET- COMPETITIVE LANDSCAPE
7.1 US Generics Market – Competitive Structure
7.2 US Generics Market – Sales Breakup of Key Players
7.3 US Generics Market – Volume Breakup of Key Players
7.4 US Generics Market – Most Prescribed Generic Drugs
7.5 US Generics Market – Market Breakup By Distribution
7.6 US Generics Market – Pricing Dynamics
8 US GENERICS MARKET – VALUE CHAIN ANALYSIS
8.1 Research and Development
8.2 Manufacturing
8.3 Marketing and Distribution
9 REGULATIONS IN THE US GENERICS INDUSTRY
9.1 Overview of Pharmaceutical Regulations
9.2 Drug Applications
9.3 Patents and Market Exclusivity
9.4 Regulatory Requirement For Generics
9.5 The Hatch-Waxman Act
9.6 Possible Certifications
9.7 Other Important Considerations
10 US GENERICS MARKET: KEY SUCCESS FACTORS
11 US GENERICS MARKET: ROAD BLOCKS
12 REQUIREMENTS FOR SETTING UP A GENERIC DRUG MANUFACTURING PLANT
12.1 Manufacturing Process
12.2 Raw Material Requirements
12.3 Machinery and Infrastructure Requirements
13 US GENERIC MARKET – KEY COMPANY PROFILES
13.1 Teva
13.2 Mylan
13.3 Actavis
13.4 Sandoz
13.5 Sun Pharma
13.6 Par Pharmaceuticals
13.7 Endo Pharmaceuticals
13.8 Lupin Pharmaceuticals
13.9 Dr Reddy’s
13.10 Hospira
LIST OF FIGURES
Figure 3 1: Structure of the Pharmaceutical Industry
Figure 3 2: Classification of Generics
Figure 4 1: United States: Patent Expiry Exposure (in Billion US$)
Figure 4 2: United States: Savings From Generic Drugs (in Billion US$), 2005-2015
Figure 5 1: Global: Generics Market: Sales Value (in Billion US$), 2011-2015
Figure 5 2: Global: Generics Market: Sales Volume (in Billion SU), 2011-2015
Figure 5 3: Global: Generics Market: Sales Value Breakup By Country (in %), 2015
Figure 5 4: Global: Generics Market: Sales Volume Breakup by Country (in %), 2015
Figure 5 5: Global: Generics Market Forecast: Sales Value (in Billion US$), 2016-2021
Figure 5 6: Global: Generics Market: Sales Volume (in Billion SU), 2016-2021
Figure 6 1: US: Pharmaceutical Market: Sales Volume (in Million Prescriptions), 2011-2015
Figure 6 2: US: Pharmaceutical Market: Sales Value (in US$ Billion), 2011-2015
Figure 6 3: US: Pharmaceutical Market: Sales Volume Breakup of Branded and Generic Drugs (in %), 2011 & 2015
Figure 6 4: US: Pharmaceutical Market: Sales Value Breakup of Branded and Generic Drugs (in %), 2011 & 2015
Figure 6 5: US: Generics Market: Sales Value (in Billion US$), 2011-2015
Figure 6 6: US: Generics Market Forecast: Sales Value (in US$ Billion), 2016-2021
Figure 6 7: US: Generics Market: Sales Volume (in Million Prescriptions), 2011-2015
Figure 6 8: US: Generics Market Forecast: Sales Volume (in Million Prescriptions), 2016-2021
Figure 6 9: US: Generics Market: Market Breakup by Segment (in %), 2011-2015
Figure 7 1: United States: Generics Market: Sales Share of Top Players (in %), 2015
Figure 7 2: United States: Generics Market: Volume Share of Top Players (in %), 2015
Figure 7 3: United States: Generics Market: Volume Share by Distribution (in %), 2015
Figure 7 4: United States: Generic Drug Prices as a Percentage of Branded Drug Prices – Based on Number of Competitors (in Billion US$)
Figure 8 1: United States – Generics Market – Value Chain Analysis
Figure 3 1: Structure of the Pharmaceutical Industry
Figure 3 2: Classification of Generics
Figure 4 1: United States: Patent Expiry Exposure (in Billion US$)
Figure 4 2: United States: Savings From Generic Drugs (in Billion US$), 2005-2015
Figure 5 1: Global: Generics Market: Sales Value (in Billion US$), 2011-2015
Figure 5 2: Global: Generics Market: Sales Volume (in Billion SU), 2011-2015
Figure 5 3: Global: Generics Market: Sales Value Breakup By Country (in %), 2015
Figure 5 4: Global: Generics Market: Sales Volume Breakup by Country (in %), 2015
Figure 5 5: Global: Generics Market Forecast: Sales Value (in Billion US$), 2016-2021
Figure 5 6: Global: Generics Market: Sales Volume (in Billion SU), 2016-2021
Figure 6 1: US: Pharmaceutical Market: Sales Volume (in Million Prescriptions), 2011-2015
Figure 6 2: US: Pharmaceutical Market: Sales Value (in US$ Billion), 2011-2015
Figure 6 3: US: Pharmaceutical Market: Sales Volume Breakup of Branded and Generic Drugs (in %), 2011 & 2015
Figure 6 4: US: Pharmaceutical Market: Sales Value Breakup of Branded and Generic Drugs (in %), 2011 & 2015
Figure 6 5: US: Generics Market: Sales Value (in Billion US$), 2011-2015
Figure 6 6: US: Generics Market Forecast: Sales Value (in US$ Billion), 2016-2021
Figure 6 7: US: Generics Market: Sales Volume (in Million Prescriptions), 2011-2015
Figure 6 8: US: Generics Market Forecast: Sales Volume (in Million Prescriptions), 2016-2021
Figure 6 9: US: Generics Market: Market Breakup by Segment (in %), 2011-2015
Figure 7 1: United States: Generics Market: Sales Share of Top Players (in %), 2015
Figure 7 2: United States: Generics Market: Volume Share of Top Players (in %), 2015
Figure 7 3: United States: Generics Market: Volume Share by Distribution (in %), 2015
Figure 7 4: United States: Generic Drug Prices as a Percentage of Branded Drug Prices – Based on Number of Competitors (in Billion US$)
Figure 8 1: United States – Generics Market – Value Chain Analysis
LIST OF TABLES
Table 4 1: United States: Sales and Patent Expiry of Major Drugs Expected to Lose Patent Protection (in Billion US$)
Table 5 1: Global – Generics Market: Sales, Volume and Growth of Major Markets, 2015
Table 7 1: United States: Generics Market: Sales Performance of Top Players (in US$ Million), 2015
Table 7 2: United States: Generics Market: Volume Performance of Top Players (in Million Prescriptions), 2015
Table 7 3: United States: Generics Market: Volume Performance of Top Generic Drugs (in Million Prescriptions), 2015
Table 9 1: United States: Overview of Pharmaceutical Regulations
Table 4 1: United States: Sales and Patent Expiry of Major Drugs Expected to Lose Patent Protection (in Billion US$)
Table 5 1: Global – Generics Market: Sales, Volume and Growth of Major Markets, 2015
Table 7 1: United States: Generics Market: Sales Performance of Top Players (in US$ Million), 2015
Table 7 2: United States: Generics Market: Volume Performance of Top Players (in Million Prescriptions), 2015
Table 7 3: United States: Generics Market: Volume Performance of Top Generic Drugs (in Million Prescriptions), 2015
Table 9 1: United States: Overview of Pharmaceutical Regulations
